Oxford BioMedica's RetinoStat achieves 'favourable safety profile' in tests
10th Oct 2016 14:19
(ShareCast News) - AIM-listed pharmaceutical Oxford BioMedica's RetinoStat, the first ocular lentiviral gene therapy to be administered in humans, demonstrated a "favourable safety profile with no serious adverse events" in its phase one study. Results of the study, which were previously published i
Read moreOxford Biomedica to raise £8.1m in placing
23rd Feb 2016 12:23
(ShareCast News) - Biopharmaceutical company Oxford Biomedica plans to raise £8.1m in a placing of 128.4m shares at 6.3p with new and existing investors. The placing, which is priced at a 10% discount to the 7p closing price on 22 February, is to provide adequate working capital for the group to con
Read moreOxford Biomedica signs 'transformational' new contract with Novartis
3rd Nov 2014 11:43
Gene and cell therapy company Oxford Biomedica has signed a 'transformational' new contract with Novartis worth up to $90m over the next three years. The group will pay $14m upfront, including a $4.3m equity subscription for a non-exclusive worldwide development and commercialisation licence in onco
Read moreFriday broker round-up UPDATE
10th Oct 2014 09:42
British American Tobacco: Goldman Sachs reduces target price from 3530p to 3250p downgrading to sell. Brown (N) Group: UBS cuts target price from 490p to 445p leaving its buy recommendation unchanged. Diageo: Goldman Sachs reduces target price from 2030p to 1925p and keeps a neutral rating. Dixons
Read moreFriday broker round-up UPDATE
11th Apr 2014 08:49
African Barrick Gold: Numis raises target price from 170p to 260p and upgrades from sell to hold. Antofagasta: Numis downgrades from hold to reduce with a target price of 700p. Ashmore Group: Jefferies ups target price from 375p to 400p and keeps a buy recommendation. JP Morgan lowers target price
Read moreOxford BioMedica posts 12.1m pound loss
10th Apr 2014 10:46
- Losses widen in challenging year - Clinical trials suspended for five months - Making solid progress throughout pipeline Shares in Oxford BioMedica plunged after it said full-year losses widened while revenue slipped after what it described as a 'challenging year.' Loss for the year of widened
Read moreOxford BioMedica wins green light to resume clinical trial recruitment
17th Oct 2013 15:43
Shares in Oxford BioMedica jumped after French and US regulators gave their approval for the biopharmaceutical group to resume recruitment for trials of three potential eye medicines it is developing with France's Sanofi. The UK company voluntarily paused recruitment into three clinical studies as
Read moreDirectors at Thorntons top up as profits return
12th Sep 2013 16:31
The Chairman of chocolatier Thorntons has boosted his stake in the company with the addition of 125,000 shares in a purchase made the same day the group revealed the restoration of its profits. Paul Wilkinson, who has held his current position since February of this year, bought the shares for 89p
Read moreThursday broker round-up UPDATE
12th Sep 2013 09:01
African Minerals: Deutsche Bank cuts target price from 550p to 450p and retains a buy recommendation. Citi lowers target price from 380p to 320p keeping a buy recommendation. Aggreko: Deutsche Bank reduces target price from 2100p to 1870p, while staying with its buy recommendation. ARM Holdings: G
Read moreOxford Biomedica wins significant government funding
11th Sep 2013 13:21
Gene therapy specialist Oxford Biomedica has been awarded a significant grant to help improve its supply chain. A UK consortium of companies won £7.7m of government funding in grants and loans, with the FTSE Fledgling company taking £7.1m of this as lead member. The consortium has been awarded, s
Read moreOxford BioMedica receives million dollar milestone payment
28th Aug 2013 09:17
Oxford BioMedica, a gene-based biopharmaceutical company, has received a one million dollar milestone payment from Pfizer. The payment was triggered by the entry of PF-06263507, a 5T4-targeted investigational antibody therapy, into human clinical trials. John Dawson, Chief Executive Officer of Oxf
Read moreQualye Munro director buys 3.3 per cent stake ahead of de-listing
16th Jul 2013 16:14
Glen Lewy, a Non-Executive Director of corporate financial advisory firm Qualye Munro bought a big stake in the company ahead of its proposed de-listing from AIM. Qualye Munro, which first debuted on the London Stock Exchange in 1993, set out proposals last week to cancel the trading of its shares
Read moreSignet CFO sells amid share-price strength
20th Jun 2013 15:35
Signet Jewelers, the largest speciality retail jewellery in the US and UK, saw its Chief Financial Officer (CFO) offload part of his stake this week following an impressive share-price rise so far this yar. Ronald Ristau, who became CFO of the dual-listed company in June 2010, sold 6,135 shares at
Read moreOxford Instruments lifts annual profit
11th Jun 2013 07:18
Oxford Instruments, which provides high-tech tools and systems for industry and research, recorded improved adjusted pre-tax profit for the year as it makes strong progress in emerging and fast growing economies while industrial markets remained soft. The FTSE 250 high-tech manufacturing and rese
Read moreOxford Biomedica Chief Scientific Officer steps down
6th Jun 2013 11:14
Gene-based biopharmaceutical company Oxford BioMedica confirmed that Dr Stuart Naylor will step down as Chief Scientific Officer at its Annual General Meeting today after 16 years with the firm. "In line with the evolution of the company's strategy, the role of Chief Scientific Officer has been rep
Read more